Obesity and Psychiatric Disorders: Frequently Encountered Clinical Questions

References

• 1 Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP: The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999; 282:1519–1522 Crossref, Google Scholar
• 2 McIntyre RS, Mancini DA, Pearce MM, Silverstone P, Chue P, Misener VL, Konarski JZ: Mood and psychotic disorders and type 2 diabetes: a metabolic triad. Can J Diabetes 2005; 29:122–132 Google Scholar
• 3 Keck PE, Buse JB, Dagogo-Jack S, D’Alessio DA, Daniels SR, McElroy SL, McIntyre RS, Sernyak MJ, Wirshing DA, Wirshing WC: Managing Metabolic Concerns in Patients With Severe Mental Illness. Minneapolis, Healthcare Information Programs, McGraw-Hill Healthcare Information Group, December 2003 Google Scholar
• 4 Osby U, Correia N, Brandt L, Ekbom A, Sparen P: Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 2000; 45(1–2):21–28 Crossref, Google Scholar
• 5 Osby U, Brandt L, Correia N, Ekbom A, Sparen P: Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844–850 Crossref, Google Scholar
• 6 McIntyre RS, Mancini DA, Pearce MM, Silverstone P, Chue P, Misener VL, Konarski JZ: Mood and psychotic disorders and type 2 diabetes: a metabolic triad. Can J Diabetes 2005; 29:122–132 Google Scholar
• 7 American Diabetes Association: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27:596–601 Crossref, Google Scholar
• 8 McIntyre RS, McCann SM, Kennedy SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46:273–281 Crossref, Google Scholar
• 9 Troiano RP, Flegal KM, Kuczmarski RJ, Campbell SM, Johnson CL: Overweight prevalence and trends for children and adolescents: the National Health and Nutrition Examination Surveys, 1963 to 1991. Arch Pediatr Adolesc Med 1995; 149:1085–1091 Crossref, Google Scholar
• 10 Lean ME, Han TS, Morrison CE: Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311(6998):158–161 Crossref, Google Scholar
• 11 Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, Saint-Vil R, Kane JM, Manu P: Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005; 162:1217–1221 Crossref, Google Scholar
• 12 Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002; 346:591–602 Crossref, Google Scholar
• 13 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76–79 Crossref, Google Scholar
• 14 Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288:1723–1727 Crossref, Google Scholar
• 15 Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998; 22:39–47 Crossref, Google Scholar
• 16 Ogden CL, Flegal KM, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 2002; 288:1728–1732 Crossref, Google Scholar
• 17 McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, and Nemeroff CB: Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004; 65:634–651 Crossref, Google Scholar
• 18 Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, Ombao H, Kupfer DJ: Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63:528–533 Crossref, Google Scholar
• 19 McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE Jr, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM: Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63:207–213 Crossref, Google Scholar
• 20 Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E: Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160:112–117 Crossref, Google Scholar
• 21 Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE: Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62:486–491 Crossref, Google Scholar
• 22 Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE: Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61:179–184 Crossref, Google Scholar
• 23 McIntyre RS, Konarski JZ: Bipolar disorder, overweight/obesity and glucose handling disorders. Current Psychiatry, in press Google Scholar
• 24 Dynes JB: Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst 1969; 30:341–344 Google Scholar
• 25 Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ: The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60:215–220 Crossref, Google Scholar
• 26 Coodin S: Body mass index in persons with schizophrenia. Can J Psychiatry 2001; 46:549–555 Crossref, Google Scholar
• 27 Homel P, Casey D, Allison DB: Changes in body mass index for individuals with and without schizophrenia, 1987–1996. Schizophr Res 2002; 55:277–284 Crossref, Google Scholar
• 28 Wyatt RJ, Henter ID, Mojtabai R, Bartko JJ: Height, weight and body mass index (BMI) in psychiatrically ill US armed forces personnel. Psychol Med 2003; 33:363–368 Crossref, Google Scholar
• 29 Stedman T, Welham J: The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 1993; 162:249–250 Crossref, Google Scholar
• 30 Sharpe JK, Hills AP: Anthropometry and adiposity in a group of people with chronic mental illness. Aust N Z J Psychiatry 1998; 32:77–81 Crossref, Google Scholar
• 31 Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26:137–141 Crossref, Google Scholar
• 32 Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH: The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74:1999–2008 Crossref, Google Scholar
• 33 Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker WW: Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158:1719–1722 Crossref, Google Scholar
• 34 McIntyre RS, Konarski JZ: Schizophrenia, overweight/obesity and glucose handling disorder. Current Psychiatry, in press Google Scholar
• 35 Tappy L, Binnert C, Schneiter P: Energy expenditure, physical activity, and body-weight control. Proc Nutr Soc 2003; 62:663–666 Crossref, Google Scholar
• 36 Speakman JR, Selman C: Physical activity and resting metabolic rate. Proc Nutr Soc 2003; 62:621–634 Crossref, Google Scholar
• 37 Hebebrand J, Sommerlad C, Geller F, Gorg T, Hinney A: The genetics of obesity: practical implications. Int J Obes Relat Metab Disord 2001; 25(suppl 1):S10–S18 Google Scholar
• 38 Gale SM, Castracane VD, Mantzoros CS: Energy homeostasis, obesity, and eating disorders: recent advances in endocrinology. J Nutr 2004; 134:295–298 Crossref, Google Scholar
• 39 Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5:279–299 Crossref, Google Scholar
• 40 Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH: The disease burden associated with overweight and obesity. JAMA 1999; 282:1523–1529 Crossref, Google Scholar
• 41 Lambert TJ, Velakoulis D, Pantelis C: Medical comorbidity in schizophrenia. Med J Aust 2003; 178(suppl):S67–S70 Google Scholar
• 42 Evans DL, Charney DS: Mood disorders and medical illness: a major public health problem. Biol Psychiatry 2003; 54:177–180 Crossref, Google Scholar
• 43 Fagiolini A, Kupfer DJ, Rucci P, Scott JA, Novick DM, Frank E: Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry 2004; 65:509–514 Crossref, Google Scholar
• 44 Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S: The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47:699–713 Crossref, Google Scholar
• 45 Casey DE: Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005; 118(suppl 2):15S–22S Google Scholar
• 46 Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287:356–359 Crossref, Google Scholar
• 47 National Cholesterol Education Program, Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497 Crossref, Google Scholar
• 48 National Institutes of Health, National Heart, Lung, and Blood Institute, Obesity Education Initiative: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, Md, National Institutes of Health, June 1998 Google Scholar
• 49 Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S: Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005; 25:255–258 Crossref, Google Scholar
• 50 Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM: Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58:565–572 Crossref, Google Scholar
• 51 McIntyre RS, Konarski JZ, Misener VL, Kennedy SH: Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17:83–93 Crossref, Google Scholar
• 52 Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB: Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 2004; 292:927–934 Crossref, Google Scholar
• 53 Fontaine KR, Barofsky I, Bartlett SJ, Franckowiak SC, Andersen RE: Weight loss and health-related quality of life: results at 1-year follow-up. Eat Behav 2004; 5:85–88 Crossref, Google Scholar
• 54 Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM: Systematic Review of the Long-Term Effects and Economic Consequences of Treatments for Obesity and Implications for Health Improvement. Health Technol Assess 2004; 8(21) Google Scholar
• 55 Raison CL, Klein HM: Psychotic mania associated with fenfluramine and phentermine use. Am J.Psychiatry 1997; 154:711 Google Scholar
• 56 Khan SA, Spiegel DA, Jobe PC: Psychotomimetic effects of anorectic drugs. Am Fam Physician 1987; 36:107–112 Google Scholar
• 57 Baptista T: Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100:3–16 Crossref, Google Scholar
• 58 James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356(9248):2119–2125 Crossref, Google Scholar
• 59 Wirth A, Krause J: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286:1331–1339 Crossref, Google Scholar
• 60 Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC: A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162:954–962 Crossref, Google Scholar
• 61 Benazzi F: Organic hypomania secondary to sibutramine-citalopram interaction. J Clin Psychiatry 2002; 63:165 Crossref, Google Scholar
• 62 Giese SY, Neborsky R: Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl. Plast Reconstr Surg 2001; 107:293–294 Crossref, Google Scholar
• 63 Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, Capece JA: Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003; 64:1449–1454 Crossref, Google Scholar
• 64 Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11:722–733 Crossref, Google Scholar
• 65 Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, Capece JA, Karvois D: Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64:1335–1341 Crossref, Google Scholar
• 66 McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, Kamin M, Hudson JI: Topiramate in the treatment of binge-eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160:255–261 Crossref, Google Scholar
• 67 Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C, Tritt K, Krawczyk J, Kettler C, Egger C, Rother WK, Loew TH: Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25:211–217 Crossref, Google Scholar
• 68 Floris M, Lejeune J, Deberdt W: Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001; 11:181–182 Crossref, Google Scholar
• 69 Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB: Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13:81–85 Crossref, Google Scholar
• 70 Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Nizatidine ftreatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 2003; 18:457–461 Crossref, Google Scholar
• 71 Baptista T, Hernandez L, Prieto LA, Boyero EC, de Mendoza S: Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001; 62:653–655 Crossref, Google Scholar
• 72 Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, Keith S: Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003; 28:527–529 Crossref, Google Scholar
• 73 Heck AM, Yanovski JA, Calis KA: Orlistat: a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20:270–279 Crossref, Google Scholar
• 74 Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C: The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 2002; 22:68–70 Crossref, Google Scholar
• 75 McIntyre RS, Konarski JZ, Keck PE: Psychotropic-induced weight gain: liability, mechanisms, and treatment approaches, in Obesity and Mental Disorders. Edited by McElroy SL, Allison DB, Bray GA. New York, Taylor and Francis, 2005, pp 307–352 Google Scholar
• 76 Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R: A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003; 54:1155–1157 Crossref, Google Scholar
• 77 Ball MP, Coons V B, Buchanan RW: A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52:967–969 Crossref, Google Scholar
• 78 Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M: Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004; 65:471–477 Crossref, Google Scholar
• 79 Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358–363 Crossref, Google Scholar
• 80 Holt RA, Maunder EMW: Is lithium-induced weight gain prevented by providing healthy eating advice at the commencement of lithium therapy? J Hum Nutr Diet 1996; 9:127–133 Crossref, Google Scholar
• 81 Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG: The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003; 35:237–241 Crossref, Google Scholar
• 82 Ball MP, Coons VB, Buchanan RW: A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52:967–969 Crossref, Google Scholar